Leerink Sees Limited Near-Term Upside for Zimmer Biomet Holdings, Inc. (ZBH) Ahead of 2027 Catalysts

We recently compiled a list of the 10 Best Healthcare Stocks to Buy and Hold for 3 Years. Zimmer Biomet Holdings, Inc. is one of the best healthcare stocks on this list.

TheFly reported on April 13 that Leerink Partners began coverage of ZBH with a Market Perform rating and a $10 price target. The initiation noted that although the stock trades at a discount compared with large-cap medical technology peers and its own historical valuation range, the overall risk and reward profile is considered balanced. The firm highlighted limited near-term upside potential ahead of more significant catalysts expected in 2027. It also pointed to near-term growth as being sensitive to shifts in market share and pricing dynamics, which could constrain performance relative to expectations in the short term.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) also announced on April 7 that it has appointed Jonathan M. Vigdorchik, M.D., as Chief Science, Technology, and Medical Affairs Officer, effective April 14, 2026. In this expanded leadership role, he will guide the company’s global technology strategy across artificial intelligence, robotics, smart implant systems, and data-driven solutions.

Leerink Sees Limited Near-Term Upside for Zimmer Biomet Holdings, Inc. (ZBH) Ahead of 2027 Catalysts

He will also oversee medical education initiatives and the company’s global advisory board, supporting stronger clinical engagement and innovation development. Dr. Vigdorchik, an orthopedic surgeon with prior experience at ZBH, brings clinical and research expertise aimed at advancing orthopedic care. His appointment is intended to strengthen the company’s innovation pipeline and accelerate the development of advanced surgical technologies.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is a global medical device company specializing in orthopedic products, including joint replacement, sports medicine, and spine solutions. It develops advanced implants and surgical technologies designed to improve mobility and quality of life for patients.

While we acknowledge the risk and potential of ZBH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ZBH and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Healthcare Stocks to Buy and Hold for 3 Years and 10 Best Beaten Down Stocks to Invest in According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.